| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | E.coli-derived human TRIM23 recombinant protein (Position: E35-R406) was used as the immunogen for the TRIM23 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
TRIM23 Antibody / Tripartite motif-containing protein 23 is a anti-TRIM23 Rabbit antibody Polyclonal (rabbit origin) supplied in Lyophilized format. Recommended for workflows such as Western blot (WB), ELISA with listed reactivity in Human, Mouse, Rat.
Key elements and design rationale
- Target: TRIM23
- Antibody details: Rabbit, Polyclonal (rabbit origin), isotype Rabbit IgG
- Format: Lyophilized
- Applications (as listed): WB, ELISA
Biological background
Functionally, TRIM23 antibody identifies a 586-amino-acid protein that regulates signaling complexes and autophagy. TRIM23 ubiquitinates and activates TBK1 kinase, promoting antiviral autophagy and interferon responses. It also coordinates endomembrane trafficking by acting as an Arf GAP (GTPase-activating protein), linking vesicular dynamics to immune signaling.
The TRIM23 gene is located on chromosome 5q12.3 and is expressed in multiple tissues, with highest levels in brain, lung, and immune cells. Through its dual ubiquitin ligase and Arf GAP activities, TRIM23 integrates membrane trafficking and host defense. It contributes to selective autophagy of pathogens and protein aggregates.
Pathologically, altered TRIM23 expression has been associated with neurodegeneration, viral infection, and cancer. In neurons, TRIM23 maintains axonal homeostasis, while in immune cells it regulates autophagic responses. Research using TRIM23 antibody supports studies in innate immunity, autophagy, and vesicle biology.
TRIM23 antibody is validated for western blotting, immunofluorescence, and immunohistochemistry to detect E3 ligases and autophagy regulators.
Structurally, Tripartite motif-containing protein 23 features a RING finger domain for E3 ligase activity, B-box and coiled-coil domains for dimerization, and a C-terminal ARF GAP domain. This antibody supports detailed analysis of TRIM23's regulatory roles in autophagy and innate immune signaling.
Research relevance and current trends
- Connecting protein-level changes to phenotype using orthogonal readouts (genetic perturbation, transcriptomics, imaging).
- Considering isoforms and post-translational regulation when interpreting protein-level changes.
- Comparing results across species and model systems with matched controls.
Common research applications
- Western blotting: compare relative abundance and activation-state changes across conditions.
- ELISA: support antibody-based quantification in assay formats where applicable.
Interpret changes in signal alongside appropriate controls and, when relevant, in parallel with total-protein or pathway readouts.
Notes for experimental interpretation
- Signal can reflect expression level, isoform composition, and post-translational state; interpret results in the context of your model system and stimuli.
- Species differences and sample matrices can influence epitope recognition; prioritize matched controls and orthogonal confirmation when feasible.
Antibody notes: Polyclonal antibodies recognize multiple epitopes, which can broaden the epitope footprint and may increase sensitivity in some contexts.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
